MedTrace Logo

AMH for the Identification of PCOM in PCOS Diagnosis

NCT05527353 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1800

Last updated 2022-09-02

No results posted yet for this study

Summary

The purpose of this study is to validate the anti-müllerian hormone (AMH) cut-off established and validated in the APHRODITE study, for the determination of PCOM as part of the diagnosis of PCOS, using the Elecsys AMH Plus immunoassay.

Conditions

  • Polycystic Ovary Syndrome

Sponsors & Collaborators

  • Roche Diagnostics GmbH

    collaborator INDUSTRY

  • Oulu University Hospital

    lead OTHER

Principal Investigators

  • Terhi T Piltonen, Professor · Oulu University Hospital, University of Oulu

Eligibility

Min Age
32 Years
Max Age
37 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-13
Primary Completion
2022-10-31
Completion
2022-12-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05527353 on ClinicalTrials.gov